UNICA IRIS Institutional Research Information System

MANTOVANI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 33.556
NA - Nord America 3.401
AS - Asia 1.261
SA - Sud America 140
AF - Africa 12
OC - Oceania 1
Totale 38.371
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 32.680
US - Stati Uniti d'America 3.353
CN - Cina 570
SG - Singapore 463
UA - Ucraina 273
SE - Svezia 200
BR - Brasile 119
GB - Regno Unito 109
DE - Germania 101
FI - Finlandia 76
KR - Corea 59
VN - Vietnam 56
IN - India 41
CA - Canada 40
FR - Francia 34
HK - Hong Kong 19
BE - Belgio 16
ES - Italia 12
JP - Giappone 11
NL - Olanda 10
PL - Polonia 9
RU - Federazione Russa 9
BD - Bangladesh 8
IR - Iran 8
TR - Turchia 7
MX - Messico 6
ZA - Sudafrica 6
AR - Argentina 5
AT - Austria 4
CL - Cile 4
LT - Lituania 4
EC - Ecuador 3
IQ - Iraq 3
LV - Lettonia 3
AL - Albania 2
AZ - Azerbaigian 2
BO - Bolivia 2
IE - Irlanda 2
JM - Giamaica 2
KZ - Kazakistan 2
LK - Sri Lanka 2
NO - Norvegia 2
PE - Perù 2
PT - Portogallo 2
PY - Paraguay 2
RO - Romania 2
TN - Tunisia 2
AM - Armenia 1
AU - Australia 1
BG - Bulgaria 1
BH - Bahrain 1
CG - Congo 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GY - Guiana 1
HU - Ungheria 1
ID - Indonesia 1
JO - Giordania 1
LA - Repubblica Popolare Democratica del Laos 1
MU - Mauritius 1
PH - Filippine 1
PS - Palestinian Territory 1
RS - Serbia 1
TW - Taiwan 1
UY - Uruguay 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 38.371
Salva come PNG Salva come JPEG
Città #
Cagliari 31.640
Uta 856
Fairfield 406
Ashburn 303
Woodbridge 264
Chandler 230
Singapore 214
Houston 203
Seattle 191
Nyköping 179
Boardman 156
Wilmington 153
Jacksonville 152
Cambridge 151
Ann Arbor 149
Dallas 146
Beijing 106
Dearborn 64
Santa Clara 61
Los Angeles 57
Seoul 51
Shanghai 51
Nanjing 49
Boston 48
New York 38
Hefei 34
Guangzhou 32
Buffalo 28
Helsinki 26
Ho Chi Minh City 25
London 23
Changsha 21
Pune 21
San Diego 21
Toronto 19
Shenyang 18
Brussels 16
Hong Kong 16
Munich 15
Tianjin 14
Milan 13
Nanchang 12
Hanoi 11
Jiaxing 11
Redondo Beach 11
The Dalles 10
Chicago 9
Jinan 9
Redwood City 9
Montreal 8
Norwalk 8
Rome 8
Orange 7
San Mateo 7
São Paulo 7
Tokyo 7
Atlanta 6
Auburn Hills 6
Hangzhou 6
Kunming 6
Phoenix 6
Turku 6
Verona 6
Warsaw 6
Ankara 5
Barcelona 5
Brandizzo 5
Chennai 5
Hebei 5
Poplar 5
Stockholm 5
Wuhan 5
Augusta 4
Belo Horizonte 4
Brooklyn 4
Colombo 4
Council Bluffs 4
Denver 4
Kilburn 4
Mountain View 4
Mumbai 4
Rio de Janeiro 4
San Francisco 4
Sassari 4
Somma Vesuviana 4
Torino 4
Curitiba 3
Detroit 3
Florence 3
Fuzhou 3
Islington 3
Johannesburg 3
Leawood 3
Monmouth Junction 3
Ningbo 3
Phủ Lý 3
Piscataway 3
Qingdao 3
Riga 3
Salerno 3
Totale 36.580
Salva come PNG Salva come JPEG
Nome #
Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy 3.549
The cachexia score (CASCO) as a tool for staging cachectic cancer patients 2.174
Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches 2.037
Advances in pharmacologic strategies for cancer cachexia 1.873
Open phase II study on efficacy and safety of an oral amino acid functional cluster supplementation in cancer cachexia 1.757
The nutritional risk in oncology: a study of 1,453 cancer outpatients 1.707
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS) 1.490
null 936
Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: Comparison between elderly and non-elderly patient response 930
Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer 927
Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients 906
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial 896
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer 864
null 819
Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters 778
Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy 745
Current medications for cancer cachexia 740
Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer 723
null 681
Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2 680
Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy 606
Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: An evaluation of effectiveness, safety and costs 581
Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes 542
Clinical and immunological evaluation of schizophyllan (SPG) in combination with standard chemotherapy in patients with head and neck squamous cell carcinoma 531
null 529
Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate 508
Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical outcome, toxicity and organ/function preservation 502
Efficacy, compliance and prognostic significance of a comprehensive geriatric assessment in the geriatric cancer patient = Efficacia, applicabilità e significato prognostico di una valutazione geriatrica multidimensionale nel paziente oncologico anziano 495
A phase II study with antioxidants, both in the diet an supplemented, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia-cachexia and oxidative stress 490
Medroxyprogesterone acetate reduces the In vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients 490
Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients 482
Role of proinflammatory cytokines and leptin in cancer-related anorexia/cachexia. Metabolic abnormalities and therapeutic approaches = Ruolo delle citochine infiammatorie e della leptina nell'anoressia/cachessia neoplastica. Aspetti metabolici e terapeutici 481
Cisplatin induces serotonin release from human peripheral blood mononuclear cells of cancer patients and methylprednisolone inhibits this effect 474
Medroxyprogesterone acetate and megestrol acetate reduce cisplatin-induced serotonin release from human peripheral blood mononuclear cells of cancer patients 462
Neo-adjuvant organ-preserving chemotherapy in the management of locally advanced oral cavity and oropharynx cancer: A tentative quantitative evaluation of organ preservation and clinical response 459
Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical response and organ/function preservation 457
Relationships betxween Fas expression, activation molecule CD25, and functional activity of tumor-associated lymphomonocytes from neoplastic effusions 446
Tumor-associated lymphomonocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokynes 432
Medroxyprogesterone acetate reduces the production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients 430
Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC 422
Neo-adjuvant (primary) organ-preserving chemotherapy in the management of locally advanced laryngeal carcinoma: Larynx preservation and clinical response 405
Anorexia/Cachexia and oxidative stress in cancer patients = Anoressia/Cachessia e stress ossidativo nei pazienti con cancro 373
Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG) 353
An innovative treatment approach for cancer-related anorexia/cachexia and oxidative stress: Background and design of an ongoing, phase III, randomized clinical trial 310
Peripheral blood lymphocyte response to exogenous interleukin 2 by PHA-prestimulated and non-PHA-prestimulated cells in patients with cancer 307
Membrane-bound and soluble IL-2 receptors (p55 and p75 chains) on peripheral blood mononuclear cells from patients with solid malignancies 271
[p55 and p75 subunits of the IL 2 receptor, membrane bound and soluble, in peripheral lymphocytes in patients with solid tumors] 220
Membrane-bound/soluble IL-2 receptor (IL-2R) and levels of IL-1α, IL-2, and IL-6 in the serum and in the PBMC culture supernatants from 17 patients with hematological malignancies 165
Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy 139
Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin 138
Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial 131
Immunologic assessment determined by response to IL-2 and immunophenotyping of tumor-infiltrating lymphocytes, of invaded and non invaded lymph nodes and of peripheral blood lymphocytes from twenty-one patients with primary laryngeal cancer 118
Lack of correlation between defective cell-mediated immunity and levels of secreted or circulating cytokines in a study of 90 cancer patients 116
Preovulatory human follicular fluid in vitro inhibits interleukin (IL)- 1α, IL-2, and production and expression of p55 chain IL-2 receptor of lymphomonocytes 107
Study of peripheral blood lymphocyte subset distribution and IL-2 receptor (IL-2 R) p55-p75 subunit expression in patients with cancer of different sites 104
[The immunological assessment of a combined therapeutic approach (chemo- + radiotherapy +/- surgery) including immunotherapy in neoplasms of the head and neck area at an advanced stage] 98
Evidence that granulosa cells inhibit interleukin-1α and interleukin-2 production from follicular lymphomonocytes 80
Medical imaging: a segmentation algorithm 18
Totale 38.484
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.278
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.278
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.696 0 0 0 0 0 1.235 831 663 143 335 369 120
2021/20221.343 108 104 90 69 154 83 60 91 118 102 158 206
2022/20232.436 185 235 180 175 175 290 71 461 164 146 211 143
2023/20243.628 245 128 131 271 356 660 389 235 196 352 304 361
2024/20254.739 389 796 834 760 493 783 278 55 91 73 102 85
2025/20261.243 161 128 330 225 253 146 0 0 0 0 0 0
Totale 38.484